On October 25, 2022, the US FDA granted accelerated approval to Tecvayli® (teclistamab-cqyv, Janssen Biotech, Inc.) for adult patients with […]
The first cell-based gene therapy for multiple myeloma has been approved by the US Food and Drug Administration. Approval of […]
According to outcomes from an ongoing phase 1 study, a bispecific BCMA (B-cell maturation antigen) x CD3 antibody named Teclistamab […]
Being the second most common type of blood cancer, 5-6% of the world population is diagnosed with Multiple Myeloma every […]